Core Insights - KalVista Pharmaceuticals has received FDA approval for EKTERLY, the first oral on-demand treatment for hereditary angioedema (HAE), which is expected to drive significant growth for the company [1] Financial Performance - For the quarter ending September 11, 2025, KalVista reported an earnings per share (EPS) of -$1.12, missing the estimated EPS of -$0.91, resulting in a negative surprise of 23.08% [2] - The company's revenue for the quarter was approximately $1.43 million, falling short of the expected $2.09 million, indicating a shortfall of 20.91% [2] - KalVista has exceeded consensus EPS estimates only once in the past four quarters, highlighting ongoing financial challenges [2] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of approximately -3.73 and an enterprise value to operating cash flow ratio of about -3.89, indicating difficulties in achieving profitability and generating positive cash flow [3] - The earnings yield is negative at approximately -26.83%, further emphasizing the company's financial struggles [3] Debt and Stability - KalVista's debt-to-equity ratio of 0.07 suggests a relatively low level of debt compared to its equity, indicating financial stability [4] - The recent FDA approval of EKTERLY positions the company for potential future growth, although the immediate impact on stock price and future earnings expectations remains uncertain [4]

KalVista Pharmaceuticals (NasdaqGM:KALV) Q1 2026 Earnings Call September 11, 2025 08:30 AM ET Company ParticipantsBen Palleiko - CEONicole Sweeny - CCOBrian Piekos - CFORyan Baker - Head of Investor RelationsConference Call ParticipantsSerge Belanger - AnalystNone - AnalystDevanjana Chatterjee - AnalystMaury Raycroft - AnalystStacy Koo - AnalystWilliam Dubin - AnalystPaul Matteis - Senior Biotechnology AnalystPete Stavropoulos - AnalystTazeen Ahmad - AnalystOperatorLadies and gentlemen, thank you for standi ...

Company Overview - KalVista Pharmaceuticals is a newly commercial stage pharmaceuticals company [2] - The company has launched its drug EKTERLY for the treatment of acute attacks of hereditary angioedema, which was approved by the FDA in early July [2] Product Launch and Approvals - EKTERLY was launched immediately after FDA approval and the company closed its first fiscal quarter as a commercial entity on July 31 [2] - The drug has also received approval from the U.K. MHRA and is set to launch in the U.K. next year [3] - The CHMP in the EU recommended approval for EKTERLY at the end of July, with formal approval expected in October [3] - KalVista is pursuing approvals in four additional countries, indicating a strategy for global expansion [3]